Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 10/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.78 |
| ▸ | MYC | P01106 | 9/20 | 0.76 |
| ▸ | MAX | P61244 | 6/20 | 0.76 |
| ▸ | IDO1 | P14902 | 4/20 | 0.72 |
| ▸ | NPC1 | O15118 | 1/20 | 0.66 |
| ▸ | RAB9A | P51151 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.64 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.62 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16107923 | 0.90 | MEN1 (0.73) | MEN1KMT2AMYCMAXIDO1 | |
| SCHEMBL16139686 | 0.89 | MEN1 (0.72) | MEN1KMT2AMYCMAXIDO1 | |
| SCHEMBL7067454 | 0.86 | MYC (1.00) | MEN1KMT2AMYCMAXIDO1 | |
| SCHEMBL16107842 | 0.86 | MEN1 (0.71) | MEN1KMT2AMYCMAXIDO1 | |
| SCHEMBL16107920 | 0.85 | MYC (1.00) | MEN1KMT2AMYCMAXIDO1 | |
| SCHEMBL16107916 | 0.85 | MYC (0.67) | MEN1KMT2AMYCMAXIDO1 | |
| SCHEMBL300125 | 0.84 | IDO1 (1.00) | MEN1KMT2AMYCMAXIDO1 | |
| SCHEMBL16107914 | 0.84 | MYC (0.66) | MEN1KMT2AMYCMAXIDO1 | |
| SCHEMBL16107913 | 0.83 | MYC (0.65) | MEN1KMT2AMYCMAXIDO1 | |
| SCHEMBL16107929 | 0.83 | MYC (0.73) | MEN1KMT2AMYCMAXIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6749645-B2 | RED AND BLUE DIRECT DYE; HAIR | WELLA AKTIENGESELLSCHAFT (DE) | 2004-06-15 | — | — | US | claimed |
| US-20020189032-A1 | Use of 4-nitro-2,1,3,-benzoxadiazole derivatives as dyes in colouring agents for keratin fibres | HFC PRESTIGE INTERNATIONAL OPERATIONS SWITZERLAND SÀRL (CH) | 2002-12-19 | — | — | US | claimed |
| US-9242944-B2 | Potent analogues of the C-Myc inhibitor 10074-G5 with improved cell permeability | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2016-01-26 | — | — | US | disclosed |
| US-9242944-B2 | Potent analogues of the C-Myc inhibitor 10074-G5 with improved cell permeability | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2016-01-26 | — | — | US | disclosed |
| US-9242944-B2 | Potent analogues of the C-Myc inhibitor 10074-G5 with improved cell permeability | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2016-01-26 | — | — | US | disclosed |
| US-20140296307-A1 | POTENT ANALOGUES OF THE C-MYC INHIBITOR 10074-G5 WITH IMPROVED CELL PERMEABILITY | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2014-10-02 | — | — | US | disclosed |
| US-20140296307-A1 | POTENT ANALOGUES OF THE C-MYC INHIBITOR 10074-G5 WITH IMPROVED CELL PERMEABILITY | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2014-10-02 | — | — | US | disclosed |
| US-20140296307-A1 | POTENT ANALOGUES OF THE C-MYC INHIBITOR 10074-G5 WITH IMPROVED CELL PERMEABILITY | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2014-10-02 | — | — | US | disclosed |
| US-6749645-B2 | RED AND BLUE DIRECT DYE; HAIR | WELLA AKTIENGESELLSCHAFT (DE) | 2004-06-15 | — | — | US | disclosed |
| US-20020189032-A1 | Use of 4-nitro-2,1,3,-benzoxadiazole derivatives as dyes in colouring agents for keratin fibres | HFC PRESTIGE INTERNATIONAL OPERATIONS SWITZERLAND SÀRL (CH) | 2002-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296307-A1 | POTENT ANALOGUES OF THE C-MYC INHIBITOR 10074-G5 WITH IMPROVED CELL PERMEABILITY | MYC, MYCBP, MKI67 | MEN1 204/4885KMT2A 1587/4885MYC 1/4885 |
| US-20020189032-A1 | Use of 4-nitro-2,1,3,-benzoxadiazole derivatives as dyes in colouring agents for keratin fibres | CBR1, CYC1, CBR3 | MEN1 4392/4885KMT2A 2588/4885MYC 2646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.